Drug Candidate for Treatment of Pulmonary Arterial Hypertension

Ralinepag (APD811), is an oral, next-generation, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). Arena discovered and developed this investigational drug candidate internally. Ralinepag’s potency on vasodilation, inhibition of proliferation of vascular smooth muscle cells, and inhibition of platelet aggregation, combined with an extended half life support its application as a potentially best-in-class agent for the treatment of PAH.

About Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. Current treatment of PAH falls within four distinct therapeutic classes: endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogues and soluble guanylate cyclase (SGc) stimulators. The available therapies have positive effects in PAH, but they do not provide a cure, and in many patients the disease will progress despite treatment.


We have received positive Phase 2 results for ralinepag and have initiated our Phase 3 ADVANCE program. In July, 2017 we completed a randomized, double-blind and placebo-controlled Phase 2 clinical trial to evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag.

Visit https://clinicaltrials.gov/ for more information.

Drug Candidate Disease Area Target Status Retained Rights
Ralinepag (APD811) Pulmonary Arterial Hypertension IP Receptor Agonist Phase 3 Ongoing Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories

Drug Candidate Ralinepag (APD811)
Disease Area Pulmonary Arterial Hypertension
Target IP Receptor Agonist
Status Phase 3 Ongoing
Retained Rights Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories

Ralinepag has not been approved by the US Food and Drug Administration or any other regulatory agency.